LIFEPHARMS, INC.

Biotech

LP10581, a novel small-molecule antifungal compound targeting fungal heat shock protein 90 (Hsp90) for treatment of drug-resistant invasive fungal infections.

Grants
$1.8M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Antifungal therapy against drug resistant fungal pathogens.$774,112
Federal grantDepartment of Health and Human Services · Phase II · Antifungal therapy against drug resistant fungal pathogens.$743,940
Federal grantDepartment of Health and Human Services · Phase I · The development of a novel antifungal for drug resistance$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2926TRPBLUE, INC.——
2927Senotrac Biotechnology LLC——
2928ILUMINOS THERAPEUTICS LLC——
2929LIFEPHARMS, INC.——
2930Nautilus Biotechnology——
2931Annias Immunotherapeutics, Inc.——
2932INDUSTRIAL SONOMECHANICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.